Talzenna .35 mg/1

Talzenna .35 mg/1 is a medication containing talazoparib, used for targeted therapy in certain cancer treatments. This oral capsule is manufactured by Pfizer Laboratories and is available in a 30-capsule pack.

Talzenna .35 mg/1 is primarily used in the treatment of specific types of cancer. It works by targeting certain enzymes involved in DNA repair, which can help slow the growth of cancer cells. Talazoparib is often prescribed for patients with BRCA mutations, aiding in the management of advanced breast and ovarian cancers.

Common effects of Talzenna .35 mg/1 may include fatigue, nausea, and anemia. Some users might experience vomiting, decreased appetite, or hair loss. These effects can vary widely among individuals, and not everyone will experience them.

Talzenna .35 mg/1 should be handled with care, following the guidance of a healthcare provider. It is important to inform your healthcare professional about any other medications you are taking to avoid potential interactions. Pregnant women or those planning to become pregnant should discuss the risks with their doctor.

Talzenna .35 mg/1 may interact with certain medications, including those that affect liver enzymes. It is advisable to avoid alcohol while taking this medication, as it can exacerbate side effects. Always consult a healthcare provider before starting or stopping any medication.